Impact of estimated total blood volume on NT-proBNP response to angiotensin receptor-neprilysin inhibition in acute heart failure: Insights from the PREMIER study.

Am Heart JAug 1, 2026 (epub)
Clinical ResearchCardiology

Kazutaka Nogi, Atsushi Tanaka, Takumi Imai et al.

✦ AI-curated · Sources linked

In 30 seconds

This post hoc analysis of the PREMIER randomized trial examined the relationship between estimated total blood volume (TBV) and NT-proBNP response to sacubitril/valsartan (Sac/Val) in acute heart failure patients. Among 372 patients analyzed, those in the high TBV group experienced a greater NT-proBNP reduction with Sac/Val compared to ACEI/ARB (-56% vs -32%; P = .001), particularly in patients with LVEF ≥40%.

Key findings

  • In the high TBV group, NT-proBNP reduction was -56% with Sac/Val versus -32% with ACEI/ARB.
  • No significant difference in NT-proBNP reduction was observed in the low TBV group.
  • In patients with LVEF <40%, Sac/Val showed greater NT-proBNP reduction in both TBV groups.
  • In patients with LVEF ≥40%, Sac/Val was more effective in the high TBV group.

Why it matters

Understanding the impact of estimated total blood volume on NT-proBNP response to heart failure treatments can help clinicians tailor therapies for better patient outcomes, particularly in acute heart failure management.

Source

PubMed · PMID 42542200

Published in Am Heart J. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.